Treatment of CMV Retinitis

Paul R. Skolnik, Susan W. Cox, Britta Wahren, G. Deray, C. Katlama, C. Jacobs, David M. Bachman, Matthew D. Davis, Douglas A. Jabs, Curtis L. Meinert, Richard L. Mowery

Research output: Contribution to journalLetterpeer-review


To the Editor: The study (Jan. 23 issue)1 of the comparative efficacy of foscarnet and ganciclovir for the treatment of cytomegalovirus (CMV) retinitis in patients with the acquired immunodeficiency syndrome (AIDS) provides important information. On October 17, 1991, the Department of Health and Human Services issued a clinical alert from the National Institutes of Health about this study. The alert was widely disseminated. It stated that patients who received foscarnet lived an average of four months longer than those who received ganciclovir. An immediate question this raises is the effect of concomitant therapy with zidovudine. The clinical alert stated…

Original languageEnglish (US)
Pages (from-to)1701-1703
Number of pages3
JournalNew England Journal of Medicine
Issue number25
StatePublished - Jun 18 1992

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Treatment of CMV Retinitis'. Together they form a unique fingerprint.

Cite this